T. Rowe Price Associates’s aTyr Pharma ATYR Stock Holding History

T. Rowe Price Associates’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-46,126	Closed	-$36K	–	3347
2026 Q1	$36K	Hold	46,126	–	–	﹤0.01%	3087
2025 Q4	$36K	Hold	46,126	–	–	﹤0.01%	3063
2025 Q3	$34K	Buy	46,126 +2,601	+6%	+$11.8K	﹤0.01%	3025
2025 Q2	$221K	Buy	+43,525	New	+$171K	﹤0.01%	2667
2021 Q4	–	Sell	-12,024	Closed	-$109K	–	3046
2021 Q3	$109K	Buy	+12,024	New	+$71.9K	﹤0.01%	2828
2016 Q2	–	Sell	-37,175	Closed	-$2.05M	–	2536
2016 Q1	$2.05M	Sell	37,175 -46,326	-55%	-$3.52M	﹤0.01%	1514
2015 Q4	$11.5M	Sell	83,501 -1,078	-1%	-$153K	﹤0.01%	1249
2015 Q3	$11.8M	Sell	84,579 -424	-0.5%	-$96.6K	﹤0.01%	1266
2015 Q2	$21.4M	Buy	+85,003	New	+$26.4M	﹤0.01%	1118

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates's ATYR Position: Q2 2026 in Review

T. Rowe Price Associates sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 46,126 shares — an estimated $36K sold.

T. Rowe Price Associates first reported a position in ATYR in Q2 2015 and held it in 9 quarters. The position peaked at $21.4M in Q2 2015. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

T. Rowe Price Associates reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
T. Rowe Price Associates sold 46,126 aTyr Pharma shares in Q2 2026, an estimated $36K.
T. Rowe Price Associates first reported a position in aTyr Pharma in Q2 2015 and held it in 9 quarters.
T. Rowe Price Associates's aTyr Pharma position peaked at $21.4M in Q2 2015.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.